HLS Therapeutics (TSX:HLS) Quality Rank


TSX:HLS HLS Therapeutics Inc TSX:HLS
66 GF Score
Price C$4.30
GF Value C$4.50
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

HLS Therapeutics Quality Rank Related Terms

TSX:HLS
66GF Score
HLS Therapeutics Inc TSX:HLS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.30 is trading 4.4% below its estimated GF Value™ of C$4.50. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • Quality Rank:
  • GF Value™: C$4.50 vs. price of C$4.30 (4.4% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
66GF Score

Get the complete analysis for TSX:HLS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.30
Price
C$4.50
GF Value